文献速递乳腺MR

乳腺MRI在治疗性乳房切除术后检测无症状复发中的作用

The Role of Breast MRI in Detecting Asymptomatic Recurrence After Therapeutic Mastectomy.
PubMed 文献 · AJR Am J Roentgenol · 2020-05-06

回顾性分析191例单侧治疗性乳房切除术后无症状患者的402次乳腺MRI,切除侧BI-RADS阳性7次(1.7%),活检证实恶性4例,阳性预测值57.1%,阴性预测值99.5%,敏感度66.7%、特异度99.2%,每1000次检查检出10例癌症;作者支持在對侧乳腺MRI检查时纳入切除侧以筛查复发。

要点

  • 治疗性乳房切除术后无症状患者中,MRI切除侧恶性检出率为每1000次检查10例癌症。
  • 切除侧BI-RADS 4类异常检查的阳性预测值为57.1%,活检阳性预测值为100%。
  • MRI诊断切除侧复发的敏感度为66.7%、特异度为99.2%、阴性预测值为99.5%。

核心结论

  • 研究结果支持在對侧乳腺MRI检查中纳入切除侧,以筛查治疗性乳房切除术后的癌症复发。

研究设计与样本

  • 回顾性记录审查,纳入2010年1月1日至2016年1月1日6年期间191例单侧治疗性乳房切除术后女性共402次乳腺MRI检查,年龄26至78岁。
  • 所有患者切除侧均无症状;从影像报告中提取切除侧BI-RADS评估,并复习电子病历获取手术及肿瘤史、临床和影像随访及病理结果。
  • 恶性由病理结果确定;良性由以下至少一项确认:病理结果、至少12个月无病临床随访记录或至少12个月无病影像随访记录。
  • 采用描述性统计和2×2列联表分析。

关键影像表现/征象

  • 402次MRI中395次(98.3%)切除侧评估为良性表现。
  • 7次(1.7%)切除侧判为阳性表现(BI-RADS 4类,可疑恶性)。
  • 7次阳性判读中4次行活检,4次活检均证实恶性,活检阳性预测值为100%。
  • 其余3次阳性未行活检,但随访影像均显示病灶改善或消退,异常检查阳性预测值为57.1%。
  • 2次MRI假阴性,即在MRI判为良性表现后12个月内出现局部复发,阴性预测值为99.5%。

诊断标准与关键数值

  • 切除侧BI-RADS 4类判为可疑恶性。
  • 敏感度66.7%、特异度99.2%。
  • 异常检查阳性预测值57.1%,活检阳性预测值100%,阴性预测值99.5%。
  • 所有MRI检查中切除侧无症状癌症检出率为每1000次检查10例癌症。

临床应用与阅片要点

  • 作者支持在對侧乳腺MRI检查时纳入切除侧,以筛查治疗性乳房切除术后的癌症复发。
  • 切除侧BI-RADS 4类病变应结合活检明确,本组活检阳性预测值为100%。
  • MRI判为良性后12个月内仍可能出现局部复发,本组假阴性2次、阴性预测值99.5%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. MRI is not routinely used to screen for cancer recurrence after therapeutic mastectomy; however, data on this topic are sparse. We performed this study to determine the utility of breast MRI in detecting asymptomatic locoregional recurrence after therapeutic mastectomy. MATERIALS AND METHODS. A retrospective record review identified all breast MRI studies performed in women who had undergone unilateral therapeutic mastectomy over a 6-year period (January 1, 2010, to January 1, 2016). A total of 402 studies were performed in 191 women between the ages of 26 and 78 years old, none of whom were experiencing symptoms on the mastectomy side. BI-RADS assessments for the mastectomy side were extracted from the radiology reports, and the electronic medical records were reviewed for surgical and oncologic history, clinical and imaging follow-up, and pathologic results. Malignancy was determined by pathologic results. Benignity was confirmed by at least one of the following: pathologic results, at least 12 months of documented disease-free clinical follow-up, or at least 12 months of documented disease-free imaging follow-up. Descriptive statistical and 2 × 2 contingency table analyses were performed. RESULTS. In all, 395 MR images (98.3%) were assessed as showing benign findings on the mastectomy side. Seven (1.7%) were interpreted as showing positive findings on the mastectomy side (BI-RADS category 4, suspicious for malignancy). Biopsy was performed in four of the seven positive interpretations. All four biopsies yielded malignancy for a positive predictive value of biopsy of 100%. The three remaining positive cases did not include biopsy; however, in each case, follow-up imaging showed improvement or resolution of the finding, yielding a positive predictive value of an abnormal examination of 57.1%. Two MRI studies were false-negative, with local recurrence within 12 months after MRI deemed to show benign findings, yielding a negative predictive value of 99.5%. Sensitivity and specificity were 66.7% and 99.2%, respectively. The cancer detection rate in the asymptomatic mastectomy side for all MRI examinations was 10 cancers per 1000 examinations. CONCLUSION. Our findings support inclusion of the mastectomy side in MRI examinations of the contralateral breast to screen for cancer recurrence after therapeutic mastectomy.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Chapman MC, Hayward JH, Woodard GA, et al. The Role of Breast MRI in Detecting Asymptomatic Recurrence After Therapeutic Mastectomy. AJR Am J Roentgenol. 2020. PMID: 32374666. doi:10.2214/AJR.19.21640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。